Arvinas’ (ARVN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Arvinas (NASDAQ:ARVN) in a report released on Tuesday,Benzinga reports. The firm currently has a $81.00 price target on the stock.

Several other equities research analysts have also commented on ARVN. Stifel Nicolaus cut their price target on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Wedbush reaffirmed an “outperform” rating and issued a $57.00 target price on shares of Arvinas in a report on Tuesday, February 11th. BMO Capital Markets reissued an “outperform” rating and set a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Finally, Guggenheim reissued a “buy” rating and set a $57.00 price objective on shares of Arvinas in a report on Wednesday, February 12th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arvinas presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.08.

Arvinas Price Performance

Arvinas stock opened at $8.30 on Tuesday. The firm has a 50 day simple moving average of $18.19 and a 200-day simple moving average of $22.33. Arvinas has a 1-year low of $7.91 and a 1-year high of $46.62. The stock has a market cap of $570.81 million, a price-to-earnings ratio of -3.00 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the company posted ($2.53) earnings per share. Equities analysts expect that Arvinas will post -3.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares of the company’s stock, valued at $2,658,911.91. The trade was a 5.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Arvinas in the 4th quarter valued at $28,000. KBC Group NV boosted its stake in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the 4th quarter valued at $171,000. Finally, Tema Etfs LLC acquired a new stake in shares of Arvinas in the 4th quarter valued at $227,000. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.